Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma
Clinical trial NCT02992483 · COMPLETED
Trial details
- NCT number
- NCT02992483
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-12
- Primary completion
- 2019-06-07
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.